Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment

Current Eye Research

Volumn 41, Issue 1, 2016, Pages 107-113

  Totan, Yüksel ^a   Güler, Emre ^b   Güraʇaç, Fatma Betül ^a  

^a TURGUT OZAL UNIVERSITY   (Turkey)

^b Ercis State Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; HEMOGLOBIN A1C; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; DRUG IMPLANT; GLUCOCORTICOID; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA FOVEA; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; DIABETIC RETINOPATHY; DRUG IMPLANT; DRUG RESISTANCE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CHRONIC DISEASE; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84953363003     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2014.1002048     Document Type: Article

References (21)

1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv of Ophthalmol 2009;54:1-32.
2. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 1999;96:10836-10841.
3. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116:73-79.
4. Wang J, Xu X, Elliott MH, Zhu M, Le YZ. Muller cellderived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes 2010;59: 2297-2305.
5. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796-1806.
6. Diabetic Retinopathy Clinical Research N. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1449.
7. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-2022.
8. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report Ophthalmology 2010;117:1078-1086.
9. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46: 1440-1444.
10. Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Bio Pharm Bull 2008; 31:1541-1546.
11. Felinski EA, Antonetti DA. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 2005;30: 949-957.
12. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-489.
13. Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008;18:941-948.
14. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142-1150.
15. Haller JA, Bandello F, Belfort Jr. R, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.
16. Haller JA, Bandello F, Belfort Jr. R, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-2460.
17. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915-923.
18. Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N, et al. Treatment of anti-vascular endothelial growth factorresistant diabetic macular edema with dexamethasone intravitreal implant. Retina 2013;34:719-724.
19. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114: 1860-1867.
20. Neuburger M, Maier P, Böhringer D, Reinhard TF, Jordan J. The impact of corneal edema on intraocular pressure measurements using goldmann applanation tonometry, Tono-Pen XL, iCare, and ORA: an in vitro model. J Glaucoma 2013;22:584-590.
21. Chylack Jr. LT, Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL, et al. The lens opacities classification system III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol 1993;111:831-836.